Business Context and Reporting Period
Passage Bio, Inc. filed a Form 8-K regarding an executive leadership transition. The report identifies October 26, 2021 as the earliest event date; the departure was announced November 1, 2021.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating financial metrics.
Material Changes Versus Prior Period
- Chief Operating Officer Jill Quigley will voluntarily leave the Company effective December 31, 2021.
- The Company stated that her departure is not related to disagreements regarding its business, operations, or strategic direction.
- Her responsibilities will be assumed by other members of the executive team; no successor COO was identified.
Separation Terms, Outlook, and Risks
- Passage Bio and Ms. Quigley entered into a Transition and Separation Agreement on October 30, 2021.
- Benefits include a lump-sum payment equal to 12 months of base salary, 12 months of COBRA premiums for Ms. Quigley and eligible dependents, her 2021 target bonus, and acceleration of certain unvested equity awards.
- Ms. Quigley will provide a general waiver and release of claims and remain subject to certain restrictive covenants.
- The filing does not disclose the dollar value of the severance, bonus, benefits, or accelerated equity awards.
- The complete agreement is expected to be filed as an exhibit to the Company’s Form 10-K for the year ended December 31, 2021.
Investor Verification Items
- Review the Form 10-K exhibit for the complete Separation Agreement and quantify its cash and equity impact.
- Assess how the executive team’s reassignment of COO responsibilities affects operations and execution.
- Confirm whether the Company appoints a permanent successor COO.
- Monitor subsequent filings for additional changes to executive compensation, equity vesting, or leadership structure.